These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 32672091)

  • 1. Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder.
    Cai MT; Zheng Y; Shen CH; Yang F; Fang W; Zhang YX; Ding MP
    Mult Scler; 2021 May; 27(6):871-882. PubMed ID: 32672091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
    Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
    Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Centrally-located transverse myelitis would facilitate the differentiation of NMOSD and MOG-AD from MS.
    Etemadifar M; Salari M; Etemadifar MR; Sabeti F; Fateh ST; Aminzade Z
    Mult Scler Relat Disord; 2022 Apr; 60():103664. PubMed ID: 35219242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and MRI measures to identify non-acute MOG-antibody disease in adults.
    Cortese R; Battaglini M; Prados F; Bianchi A; Haider L; Jacob A; Palace J; Messina S; Paul F; Wuerfel J; Marignier R; Durand-Dubief F; de Medeiros Rimkus C; Callegaro D; Sato DK; Filippi M; Rocca MA; Cacciaguerra L; Rovira A; Sastre-Garriga J; Arrambide G; Liu Y; Duan Y; Gasperini C; Tortorella C; Ruggieri S; Amato MP; Ulivelli M; Groppa S; Grothe M; Llufriu S; Sepulveda M; Lukas C; Bellenberg B; Schneider R; Sowa P; Celius EG; Proebstel AK; Yaldizli Ö; Müller J; Stankoff B; Bodini B; Carmisciano L; Sormani MP; Barkhof F; De Stefano N; Ciccarelli O;
    Brain; 2023 Jun; 146(6):2489-2501. PubMed ID: 36515653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
    Juryńczyk M; Tackley G; Kong Y; Geraldes R; Matthews L; Woodhall M; Waters P; Kuker W; Craner M; Weir A; DeLuca GC; Kremer S; Leite MI; Vincent A; Jacob A; de Sèze J; Palace J
    J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):132-136. PubMed ID: 27951522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain lesion distribution criteria distinguish demyelinating diseases in China.
    Cai MT; Zhang YX; Zheng Y; Yang F; Fang W; Shen CH; Ding MP
    Ann Clin Transl Neurol; 2019 Oct; 6(10):2048-2053. PubMed ID: 31566925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards imaging criteria that best differentiate MS from NMOSD and MOGAD: Large multi-ethnic population and different clinical scenarios.
    Carnero Contentti E; Rojas JI; Criniti J; Lopez PA; Daccach Marques V; Soto de Castillo I; Tkachuk V; Marrodan M; Correale J; Farez MF; Kim HJ; Hyun JW; Messina S; Mariano R; Rocca MA; Cacciaguerra L; Filippi M; Palace J; Juryńczyk M
    Mult Scler Relat Disord; 2022 May; 61():103778. PubMed ID: 35452969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Joint radiomics and spatial distribution model for MRI-based discrimination of multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin-oligodendrocyte-glycoprotein-IgG-associated disorder.
    Luo X; Li H; Xia W; Quan C; ZhangBao J; Tan H; Wang N; Bao Y; Geng D; Li Y; Yang L
    Eur Radiol; 2024 Jul; 34(7):4364-4375. PubMed ID: 38127076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis.
    Hyun JW; Huh SY; Shin HJ; Woodhall M; Kim SH; Irani SR; Lee SH; Waters P; Kim HJ
    Mult Scler; 2019 Apr; 25(4):585-590. PubMed ID: 29512413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: A comparative study in Chinese Han patients.
    ZhangBao J; Huang W; Zhou L; Wang L; Chang X; Lu C; Zhao C; Lu J; Quan C
    Eur J Neurol; 2021 Apr; 28(4):1308-1315. PubMed ID: 33220172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
    Yan Y; Li Y; Fu Y; Yang L; Su L; Shi K; Li M; Liu Q; Borazanci A; Liu Y; He Y; Bennett JL; Vollmer TL; Shi FD
    Sci China Life Sci; 2016 Dec; 59(12):1270-1281. PubMed ID: 26920678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.
    Cortese R; Prados Carrasco F; Tur C; Bianchi A; Brownlee W; De Angelis F; De La Paz I; Grussu F; Haider L; Jacob A; Kanber B; Magnollay L; Nicholas RS; Trip A; Yiannakas M; Toosy AT; Hacohen Y; Barkhof F; Ciccarelli O
    Neurology; 2023 Jan; 100(3):e308-e323. PubMed ID: 36192175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI differences between MOG antibody disease and AQP4 NMOSD.
    Salama S; Khan M; Shanechi A; Levy M; Izbudak I
    Mult Scler; 2020 Dec; 26(14):1854-1865. PubMed ID: 31937191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.
    Yang L; Li H; Xia W; Quan C; Zhou L; Geng D; Li Y
    Eur Radiol; 2020 Mar; 30(3):1470-1479. PubMed ID: 31748853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative evaluation of different neuromyelitis optica spectrum disorder sets of criteria.
    Papeix C; Beigneux Y; Maillart E; de Seze J; Lubetzki C; Vukusic S; Collongues N; Marignier R
    Eur J Neurol; 2020 Nov; 27(11):2250-2256. PubMed ID: 32559008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.